Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review

“…Proteasome inhibitors used as monotherapy were reported in nine studies in MM ( 69 , 70 , 80 , 81 , 83 , 94 , 95 , 98 , 135 ) and three in NHL ( 109 , 123 , 126 ). In addition, 18 studies in MM ( 71 , 76 – 78 , 82 , 84 – 87 , 89 , 90 , 93 , 96 – 99 , 136 ) and two studies in NHL ( 107 , 124 ) reported the use in combination with other agents ( Table 4 ).…”

“…Bortezomib was evaluated in nine studies as monotherapy [seven in MM ( 69 , 81 , 83 , 94 , 95 , 98 , 135 ) and two in NHL ( 109 , 126 )] and in 15 studies (14 in MM ( 71 , 74 , 76 – 78 , 82 , 84 – 86 , 89 , 90 , 96 , 98 , 136 ) and one in NHL) in combination with other therapies. No studies reported the use of bortezomib in patients with CLL.…”

“…Sinopulmonary bacterial infections were reported in 15.7% ( 54 , 59 , 66 ), 8.5% ( 68 , 91 ), and 7.8% ( 110 , 113 , 115 , 122 , 124 , 127 , 128 , 134 ) of patients with CLL, MM, and NHL, respectively, when treated with B-lineage monoclonal antibodies as monotherapy ( Table 6 ). In patients who received proteasome inhibitor as monotherapy, sinopulmonary bacterial infections were reported in 7.7% ( 69 , 70 , 80 , 81 , 83 , 94 , 95 , 98 , 135 ) of patients with MM. In patients treated with kinase monotherapy, sinopulmonary bacterial infections were reported in 8.0% of patients with CLL ( 51 , 60 , 62 ).…”

Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study

“…10 However, in the area of multiple myeloma-particularly in RRMM-, sociodemographic characteristics of study participants (aside from sex and age) are rarely reported, even in studies investigating these patients in the real-world setting. [15][16][17][18][19][20][21] Furthermore, most of these studies are focused on specific therapeutic agents, thus losing sight of the general profile of RRMM. Our analysis made it possible to provide an archetypal sociodemographic profile of RRMM patients in Spain, who are mostly men or women in their 60s or 70s, retired and living in an urban area with their relatives.…”

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

“…In the REBOUND trial, retreatment with a bortezomibbased regimen induced an ORR of 71% and a median PFS of 15 months. Retreatment with Vd was well tolerated, with a limited rate of PN 15 . The evidence generated by our study represents a proof-of-concept, suggesting that early retreatment in MM patients who previously benefited from a bortezomib-based therapy -with the aim of preventing MM-related anemia, bone lesions, renal failure and hypercalcemiais feasible and effective.…”